Cellectis CLLS 深 滬
已收盤 09-20 16:00:00 美东时间
2.257
-0.063
-2.72%
華盛通- 最 高2.3335
- 今 開2.3335
- 成交量 7540股
- 最 低 2.2132
- 昨 收 2.32
- 總市值 1.62亿
- 52周最高 3.7735
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 0.9628
- 委 比 -99.50%
- 總股本 7175.12万
- 歷史最高 50.00
- 量 比 0.52
- 振 幅 5.19%
- 歷史最低 0.9628
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cellectis’ Breakthrough in TNBC Therapy
Cellectis SA (CLLS) has released an update. Cellectis SA, a leader in gene-edit...
09-04 05:00
Cellectis Reveals Promising Cancer Therapy Breakthrough
Cellectis SA (CLLS) has released an update. Cellectis SA, a clinical-stage biop...
08-27 04:57
Cellectis Publishes A 'Molecular Therapy' Article On A SMART DUAL CAR T-Cell Approach For Treating Recalcitrant Solid Tumors
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Molecular Therapy
08-27 04:34
Cellectis names Adrian Kilcoyne as chief medical officer
Cellectis (NASDAQ:CLLS) said it has appointed Adrian Kilcoyne as its chief medical officer, effective immediately. Prior to joining the firm, Kilcoyne was the chief medical officer and head of researc...
08-07 18:20
Cellectis S.A. Unveils Mid-Year Financial Report
Cellectis SA (CLLS) has released an update. Cellectis S.A., a company operating...
08-07 05:01
新浪财经ESG：CLLS 路孚特（Refinitiv）ESG评级调降至C-
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
07-22 07:00
Cellectis Shareholders Approve Key Resolutions
Cellectis SA (CLLS) has released an update. At Cellectis SA’s Annual Shareholde...
06-29 05:30
Cellectis Shareholders Support Management’s Vision
Cellectis SA (CLLS) has released an update. Cellectis, a biotech firm focused o...
06-29 04:57
Cellectis Pioneers Non-Viral Gene Therapy for SCD
Cellectis SA (CLLS) has released an update. Cellectis, a clinical-stage biotech...
06-13 04:58
Cellectis gets EU orphan drug designation for UCART22 for ALL
Cellectis (NASDAQ:CLLS) said it has received orphan drug designation from EU regulators for its allogeneic CAR-T product candidate UCART22 for the treatment of acute lymphoblastic leukemia, or ALL. Th...
06-05 06:05
